Timing of androgen deprivation for prostate cancer: Benefits versus side effects - A patient-physician dialogue

Urology

Volumn 60, Issue 5, 2002, Pages 735-737

  Soloway, Mark S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; DOCTOR PATIENT RELATION; EDITORIAL; HORMONE DETERMINATION; HUMAN; MEDICAL SPECIALIST; MORBIDITY; ONCOLOGY; ONSET AGE; PRIORITY JOURNAL; PROSTATE CARCINOMA; SIDE EFFECT;

ANDROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0036845696     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01964-7     Document Type: Editorial

References (16)

1. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
2. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 341:1999;1781-1788.
3. Granfors T., Modig H., Damber J.-E., et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for non-metastatic prostate cancer with or without pelvic lymph node involvement a prospective randomized study . J Urol. 159:1998;2030-2034.
4. Prostate Cancer Working Party Investigators Group . Immediate versus deferred treatment for advanced prostatic cancer initial results of the Medical Research Council . Br J Urol. 79:1997;235-246.
5. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy report of Radiation Therapy Oncology Group protocol 85 . J Clin Oncol. 15:1997;1013-1021.
6. Pilepich M.V., Winter K., Fu K., et al. Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Proceedings of the American Society for Clinical Oncology (ASCO) Meeting, Los Angeles, CA. (abstract) J Clin Oncol. 17:(suppl):1998;308a.
7. Byar D.P. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 32:1973;1126-1130.
8. Byar D.P., Corle D.K. Hormone therapy for prostate cancer results of the Veterans Administration Cooperative Urological Research Group studies . NCI Monogr. 7:1988;165-170.
9. Walsh P.C., DeWeese T.L., Eisenberger M.A. A structured debate immediate versus deferred androgen suppression in prostate cancer - evidence for deferred treatment . J Urol. 166:2001;508-516.
10. Fourcade R.O. Letter to the editor. J Urol. 167:2002;651-653.
11. Kirk D. Letter to the editor. J Urol. 167:2002;652-653.
12. Eisenberger M.A., Walsh P.C. Early androgen deprivation for prostate cancer? N Engl J Med. 341:1999;1837-1838.
13. Zincke H., Lau W., Bergtralh E., et al. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol. 166:2001;2208-2215.
14. Zagars G.K., Pollack A., von Eschenbach A.C. Addition of radiation therapy to androgen ablation improves outcome for sub-clinically node-positive prostate cancer. Urology. 58:2001;233-239.
15. Studer U.E., Hauri D., Dietrich D. Immediate vs deferred hormonal therapy for prostate cancer patients not suitable for curative local treatment. J Urol. 167:2002;303.
16. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93: 979-989, 2001.